Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access. Better health
Read our guide to Generic and biosimilars medicines market and pricing
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

10.02.2020
Pleased to announce that @Teva_UK 's Dr Andrew Ellis has been announced as the new chair of the British Biosimilars Association. https://t.co/AUipO5QT4G
07.02.2020
RT @biosciencetoday: Warwick Smith, director general of the @BritBiosimilars, outlines how the UK has grown into a #biosimilar medicines market leader https://t.co/2tdxdhSPAZ
07.02.2020
Read our reaction to @trussliz announcement on trade deal approach with non EU nations. https://t.co/uILEtmYFqT
18.12.2019
WHO prequalifies first biosimilar medicine to increase worldwide access to life-saving breast cancer treatment https://t.co/uWBeVJ4vIL
18.12.2019
RT @biosciencetoday: Biosimilar medicines are playing an important role in providing choice for clinicians and increasing access for patients by driving down cost to the NHS. @BritBiosimilars https://t.co/2tdxdhSPAZ